InSitu Biologics

InSitu Biologics, an emerging biotechnology company led by President and CEO James Segermark, has launched a new non-opioid pain relief drug called AnestaGel. Preclinical studies have shown that AnestaGel provides long-lasting pain relief and has been proven effective for postoperative regional pain management in surgeries such as fractures, cosmetic procedures, hip/knee replacements, and hernia repairs.